Guggenheim initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $6 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment
- Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate
- Unicycive presents new patient-level data from Phase 2 study of OLC
- Buy Rating for Unicycive Therapeutics Amid Favorable Risk/Reward and Strategic Growth Opportunities
- Promising Prospects for Unicycive Therapeutics: Buy Rating Backed by Upcoming Milestones and Strategic Preparations